Vedere Bio II presents positive new data supporting its own platform at the 25th ASGCT Conference

Data from oral presentations identify three novel AAV capsids with high retinal transduction

Additional data support the usefulness of new cell lines for efficient AAV production

Cambridge, Massachusetts, May 19, 2022 / PRNewswire /-VedereBioII, Inc., developing innovative next-generation therapies for vision recovery and preservation, today announces new preclinical data on the 25th.^th Annual Meeting of the American Society for Gene and Cell Therapy (ASGCT) Washington DCAnd in fact, May 16-19, 2022..

“These data represent significant advances in the field of ocular gene therapy, which include three new AAV capsids that provide superior retinal transduction and the production of AAV vectors at higher potency and percent. This is because we have identified a new cell line that enables us.-Full capsid. ” Dr. Gabor Veres, Chief Scientific Officer of Vedere Bio II, said. “In summary, these advances not only increase the chances of success for Vedere’s lead program, but also the ability to build pipelines and expand production of high-quality vector preps.”

The data from the ASGCT presentation is summarized below.

Three unique AAV capsids are highly efficient for transduction of retinal cells after intravitreal (IVT) injection.

Oral title: Novel AAV capsids for intravitreal delivery: Identification and characterization of novel AAV variants in non-human primates (Summary # 1199)
Date / Time / Location: Thursday, May 19, 2022 from 11:15 AM-11: 30 AM In ballroom A
Session: New AAV Capsids for Brain, Eyes and Kidneys
Main result:

• The internal limiting membrane (ILM) is a physical barrier on the retina that prevents therapeutic agents such as adeno-associated virus (AAV) from reaching the lesioned retinal cells by intravitreal injection (IVT).
• To overcome this barrier, we used a directed evolutionary approach to identify three new capsids:
• Shows excellent transduction efficiency for retinal cells and transduces all retinal layers of non-human primates
• Shows reduced off-target transduction (ciliary body)
• Limit inflammatory response (preclinical assay in non-human primates)
• Shows more efficient production potential (more than twice the parent AAV2 serotype)

The new cell line enables the production of AAV vectors with higher titers and percent flucapsids

Poster Title: X-RAP ™ Suspension Cell Line and Its Platform: Vedere’s Solution for RAAV Manufacturing (Summary # 416)
Date / Time / Location: Monday, May 16, 2022 from From 5:30 pm to 6:30 pm In Hall D
Session: Vector Product Engineering, Development or Manufacturing I
Main result:

• Producing AAV vectors with high titers and percent full capsids is essential for both commercial viability and clinical success (if given regulatory requirements).
• Vedere has successfully developed a floating cell line (X-RAP ™). This indicates zero cell aggregation in high density cultures, low nutrient consumption, 5 times the proportion of full capsid, and about 1.8 times the titer of commercially available cell lines. (Gibco ™ virus-producing cells) For rAAV production.
• Performance was consistent with different cell passage stages, different scale shaking flasks, and 2L bioreactors. Vedere plans to expand production to 50L bioreactors to ensure performance is consistent in industrial scale processes.

About Vedere Bio II, Inc.
Vedere Bio II is a privately owned emerging biopharmaceutical company that leverages proprietary optogenetics and optical switch technology and the new AAV Capsid to restore vision in all patients with visual loss due to photoreceptor cell death. is. Vedere Bio II is made up of a diverse team of pioneering scientists and drug developers to discover and develop next-generation eye treatments to restore and maintain vision in these patients.The head office is Cambridge, Massachusetts It is funded by Atlas Ventures, Octagon Capital, Mission BioCapital, Samsung BioCapital, RD Fund and Casdin Capital. For more information, please visit: www.vederebio.com Or follow Vedere Bio II twitter When LinkedIn..

See Sources BioII, Inc.